Eli Lilly & Co. (LLY)

113.19
NYSE : Health Technology
Prev Close 111.39
Day Low/High 111.33 / 113.82
52 Wk Low/High 101.36 / 132.13
Avg Volume 3.19M
Exchange NYSE
Shares Outstanding 960.13M
Market Cap 106.95B
EPS 3.10
P/E Ratio 24.75
Div & Yield 2.58 (2.21%)
The Economy is Riding the Rails: Cramer's 'Mad Money' Recap (Wednesday 4/17/19)

The Economy is Riding the Rails: Cramer's 'Mad Money' Recap (Wednesday 4/17/19)

If you want a good read on the economy, look at the details of CSX's latest earnings report.

Jim Cramer: Want a Snapshot of the Economy? Look at the Rails

Jim Cramer: Want a Snapshot of the Economy? Look at the Rails

When you see that money pouring out of the market it is going to be looking for a home. The home will most likely want some economic sensitivity.

Stock Picking Comeback: Cramer's 'Mad Money' Recap (Thursday 3/28/19)

Stock Picking Comeback: Cramer's 'Mad Money' Recap (Thursday 3/28/19)

Lots of IPOs and innovation will reward investors who do their homework, Jim Cramer says.

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

In this day and age, companies must be 'disruptors' or get left in the dust.

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

David Tepper's Appaloosa LP renews calls for changes at the top.

Eli Lilly Stock Drops After Launching Cheaper Version of Top-Selling Insulin

Eli Lilly Stock Drops After Launching Cheaper Version of Top-Selling Insulin

Eli Lilly shares traded lower Monday after it said it plans to launch a cut-price version of its top selling insulin treatment Humalog as pressure to lower drug costs continues to ripple through the pharmaceutical industry.

The Ones That Got Away: Cramer's 'Mad Money' Recap (Thursday 2/28/19)

The Ones That Got Away: Cramer's 'Mad Money' Recap (Thursday 2/28/19)

Jim Cramer lists the great stocks and the obvious winners he wishes he had talked about more.

Jim Cramer: How to Win Now, With or Without China

Jim Cramer: How to Win Now, With or Without China

If we can advance without China then who the heck knows where we can go with it.

3 Pet Product Stocks Ready to Be Unleashed: Dogness, Elanco and Zoetis

3 Pet Product Stocks Ready to Be Unleashed: Dogness, Elanco and Zoetis

Pets can bring significant profits to companies that cater to this niche market.

Hagens Berman: Judge Denies Insulin Makers' Motion To Dismiss Class-Action Lawsuit Regarding Skyrocketing Insulin Prices

Hagens Berman: Judge Denies Insulin Makers' Motion To Dismiss Class-Action Lawsuit Regarding Skyrocketing Insulin Prices

Today, a federal judge's opinion has greenlighted a national class-action lawsuit filed against Sanofi, Novo Nordisk and Eli Lilly for their systematic overpricing of insulin and concealment of a behind-the-scenes arrangement orchestrated to hike insulin...

How to Fatten Up Your Portfolio By Investing in the Obesity Epidemic

How to Fatten Up Your Portfolio By Investing in the Obesity Epidemic

As the U.S. and the world grow fatter, some investors are seeing green as they bulk up on stocks of companies on the front-lines of this 21st century Battle of the Bulge.

Stocks End Lower as Wall Street Gets No Boost From State of the Union

Stocks End Lower as Wall Street Gets No Boost From State of the Union

Stocks ended lower Wednesday as investors found little in Donald Trump's State of the Union address to warrant extending recent market gains.

Eli Lilly Misses Q4 Earnings, Cuts 2019 Outlook After Loxo Oncology Deal

Eli Lilly Misses Q4 Earnings, Cuts 2019 Outlook After Loxo Oncology Deal

Eli Lilly posted weaker-than-expected fourth quarter earnings Tuesday, and lowered its 2019 profit guidance to reflect the impact of its planned acquisition of Loxo Oncology.

Small-Caps Are Making Big Moves in This Technically Extended Market

Small-Caps Are Making Big Moves in This Technically Extended Market

Focus on individual stock picking, and take a look at small-caps, as earnings season continues.

Donald Trump, China Trade, Disney, Snap and GM - 5 Things You Must Know

Donald Trump, China Trade, Disney, Snap and GM - 5 Things You Must Know

U.S. stock futures mixed as investors remain worried the U.S. and China could fail to reach a trade agreement following Donald Trump's State of the Union address; Walt Disney rises as earnings beat estimates but expenses could rise from the company's new digital offerings; Snap soars as losses narrow and its user growth stabilizes.

Take Some Profits on This Strength: Market Recon

Take Some Profits on This Strength: Market Recon

The market can still go higher, but the time has come for the slope of price discovery to normalize a bit.

Eli Lilly Is Trading Strong Ahead of Earnings on Wednesday

Eli Lilly Is Trading Strong Ahead of Earnings on Wednesday

Jim Cramer said that Eli Lilly was the best of the pharmaceutical companies as he looked at the companies reporting earnings this week.

Bulls vs. Bears: Cramer's 'Mad Money' Recap (Friday 2/1/19)

Bulls vs. Bears: Cramer's 'Mad Money' Recap (Friday 2/1/19)

Jim Cramer makes sense of this market action and has your game plan for next week.

Pfizer And Lilly Announce Top-Line Results From Second Phase 3 Study Of Tanezumab In Osteoarthritis Pain

Pfizer And Lilly Announce Top-Line Results From Second Phase 3 Study Of Tanezumab In Osteoarthritis Pain

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.

Weakness From CAT and NVDA Support Our Repositioning Efforts

The big week of corporate earnings is upon us.

The Market Starts Rotating: Cramer's 'Mad Money' Recap (Thursday 1/24/19)

The Market Starts Rotating: Cramer's 'Mad Money' Recap (Thursday 1/24/19)

Thursday's market action showed signs investors are moving away from safety plays, Jim Cramer says.

Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil

Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil

These themes are working despite the turmoil in Washington and slowing global growth.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Big pharma is shaping up to be a consolidating category in 2019.

Eli Lilly Slides as Sarcoma Treatment Fails in Phase 3 Trial

Eli Lilly Slides as Sarcoma Treatment Fails in Phase 3 Trial

Eli Lilly falls as a Phase 3 trial of drug for treatment of sarcoma didn't meet its primary endpoint.

Notable Friday Option Activity: LLY, ATEN, FRO

Notable Friday Option Activity: LLY, ATEN, FRO

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Lilly (Eli) & Co , where a total volume of 44,518 contracts has been traded thus far today, a contract volume which is representative of approximately 4.5 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 86.7% of LLY's average daily trading volume over the past month, of 5.1 million shares.

Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative

Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative

So far 2019 is proving to be a year where things have a habit of working out right.

Banks Are Leading: Cramer's 'Mad Money' Recap (Wednesday 1/16/19)

Banks Are Leading: Cramer's 'Mad Money' Recap (Wednesday 1/16/19)

Jim Cramer looks at the run in the financial stocks and says banks are leading this market back.

Ligand Pharmaceuticals Tumbles After Short-Seller Andrew Left Slams the Stock

Ligand Pharmaceuticals Tumbles After Short-Seller Andrew Left Slams the Stock

Left's firm Citron Research gives the $100+ stock a $35 price target.

Jim Cramer: There's a Ton More Deals in the Pipe

Jim Cramer: There's a Ton More Deals in the Pipe

Deals that simply were unworkable four months ago because of price are now being done with alacrity.

Goldman's Gold Standard in M&A Bolsters Outlook for 2019

Goldman's Gold Standard in M&A Bolsters Outlook for 2019

Goldman is top of the heap for takeovers.

TheStreet Quant Rating: B- (Buy)